VNDA News and Press, Vanda Pharmaceuticals Inc.

2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...

2024-06-27 08:44:55 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much ...

2024-06-20 07:01:38 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much ...

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders PR Newswire WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq...

2024-06-17 21:59:38 ET Summary Vanda Pharmaceuticals’ portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA’s upcoming pipeline features milsaperidone and tradipitant, wi...

2024-06-13 09:00:26 ET Read the full article on Seeking Alpha For further details see: Vanda Pharmaceuticals gains as Future Pak raises offer to $8.50-$9 a share

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Vanda Pharmaceuticals stock, would like to learn m...

A look at the top 10 most actives in the United States Nauticus Robotics Inc. (KITT) rose 29.5% to $0.1787 on volume of 92,016,620 shares Freight Technologies Inc. (FRGT) rose 92.0% to $1.2 on volume of 65,878,105 shares Aethlon Medical Inc. (AEMD) rose 68.2% to $0.7379 on volume of 48,98...